Direxion Daily S&P Biotech Bull 3X ETF (LABU)
| Assets | $529.06M |
| Expense Ratio | 0.96% |
| PE Ratio | n/a |
| Shares Out | 2.92M |
| Dividend (ttm) | $1.23 |
| Dividend Yield | 0.66% |
| Ex-Dividend Date | Dec 23, 2025 |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| Volume | 442,755 |
| Open | 182.58 |
| Previous Close | 181.48 |
| Day's Range | 181.35 - 192.30 |
| 52-Week Low | 48.22 |
| 52-Week High | 212.45 |
| Beta | 2.50 |
| Holdings | 167 |
| Inception Date | May 28, 2015 |
About LABU
Fund Home PageThe Direxion Daily S&P Biotech Bull 3X ETF (LABU) is an exchange-traded fund that is based on the S&P Biotechnology Select Industry index. The fund provides daily 3 times exposure to the S&P Biotechnology Select Industry Index. LABU was launched on May 28, 2015 and is issued by Direxion.
Top 10 Holdings
39.95% of assets| Name | Symbol | Weight |
|---|---|---|
| Dreyfus Govt Cash Man Ins | n/a | 16.85% |
| Goldman Sachs Fin Gov 465 Institut | n/a | 4.70% |
| Goldman Finl Sq Trsry Inst 506 | n/a | 4.34% |
| S&P Biotechnology Select Industry Index Swap | n/a | 4.17% |
| S&P Biotechnology Select Industry Index Swap | n/a | 2.46% |
| S&P Biotechnology Select Industry Index Swap | n/a | 2.05% |
| S&P Biotechnology Select Industry Index Swap | n/a | 1.60% |
| Revolution Medicines, Inc. | RVMD | 1.30% |
| Travere Therapeutics, Inc. | TVTX | 1.28% |
| TG Therapeutics, Inc. | TGTX | 1.18% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 23, 2025 | $0.90971 | Dec 31, 2025 |
| Sep 23, 2025 | $0.10273 | Sep 30, 2025 |
| Jun 24, 2025 | $0.21897 | Jul 1, 2025 |
| Mar 25, 2025 | $0.10714 | Apr 1, 2025 |
| Jun 25, 2024 | $0.15021 | Jul 2, 2024 |
| Mar 19, 2024 | $0.16064 | Mar 26, 2024 |
Performance
LABU had a total return of 278.27% in the past year, including dividends. Since the fund's inception, the average annual return has been -22.55%.
News
Want Diversified Upside in Biotechnology? Check out LABU
Watch the Direxion Daily S&P 500 Biotech Bull 3X Shares (NYSEARCA: LABU) if you want a speculative play in the biotechnology industry with amplified volatility. This ETF attempts to mimic 3X the one-d...
Where to Buy Booming Biotech ETFs
Discover why biotech stocks are surging despite large fund outflows. Monitor these three industry ETFs for "buy the dip" opportunities.
Jablonski: Biotech presents a good buying opportunity
Sylvia Jablonski of Direxion discusses why biotech stocks and ETFs are attractive right now, due to their cheapness relative to the rest of the market.